Hosted on MSN
Alvotech completes $108 million convertible bond offering to drive R&D and biosimilar launches
Alvotech ( (ALVO)) has issued an update. Alvotech successfully completed the placement of $108 million senior unsecured convertible bonds on December 17, 2025, in a highly oversubscribed offering ...
December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan facility, Alvotech has secured ...
Alvotech recently amended its credit agreement to add a new US$75 million term loan facility led by GoldenTree Asset ...
Alvotech (ALVO) announced an amendment to its existing credit agreement, securing a new term loan facility of up to $75M. The financing was led by long-term partner GoldenTree Asset Management LP ...
Alvotech anticipates the gross proceeds from the Offering and concurrent private placement to be approximately $125 million. The allocation of ordinary shares between the Offering and concurrent ...
Alvotech (NASDAQ:ALVO) is one of the penny stocks with explosive growth potential. On June 18, Alvotech closed its ...
Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and ...
Appointment of Linda Jónsdóttir as Chief Financial Officer strengthens Alvotech's leadership team with her extensive experience across multiple industries. Joel Morales will continue to support the ...
Alvotech, the Icelandic holdout battling AbbVie in court over its Humira biosimilar, has reached an accord with the U.S. pharma giant. With a settlement in place, the companies are putting all patent ...
Alvotech acquires Xbrane's R&D operations and biosimilar candidate XB003 for ~$27M, expanding into Sweden's life sciences sector. Xbrane retains key preclinical assets, strengthens finances, and ...
Feb 15 (Reuters) - Alvotech (ALVO.O), opens new tab said on Thursday it has reached settlement agreements with Johnson & Johnson (JNJ.N), opens new tab for launching a biosimilar of the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results